# Tesamorelin

Canonical source: https://retacompare.com/encyclopedia/tesamorelin

Stabilized full-length GHRH analog. Lipid modification protects against DPP-4 cleavage.

Reference facts

Also known asEgrifta, TH9507CategoryGrowth Hormone & GhrelinMechanism of actionStabilized full-length GHRH analog. Lipid modification protects against DPP-4 cleavage.TargetsGHRHRIndications under research or approvedHIV-associated lipodystrophy (visceral adipose reduction)Regulatory status (reference entry)FDA-approved (2010)Half-life~26 minutes (subcutaneous)SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLSequence notes44-residue full-length human GHRH (1-44) NH2 with a trans-3-hexenoyl group attached to the N-terminal tyrosine.Molecular weight (Da)5135Originator / sponsorTheratechnologiesFirst reported2007
    Primary References

Falutz et al., NEJM 2007 (Tesamorelin pivotal)

Egrifta FDA label


    Explore research articles about Tesamorelin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Falutz et al., NEJM 2007 (Tesamorelin pivotal): https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- Egrifta FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf